Reading the adjunct evidence the way a reviewer would The pivotal liraglutide trials, ADJUNCT ONE and TWO, showed HbA1c effects below the regulatory threshold alongside dose-related ketosis and symptomatic hypoglycaemia, and the FDA did not approve liraglutide for type 1 on efficacy and safety grounds.6 The newer story is the automated-insulin-delivery era: ADJUST-T1D paired weekly semaglutide with an AID system in 72 adults with type 1 and obesity, and a composite goal (time in range above 70%, time below range under 4%, and at least 5% weight loss) was met by 36% versus 0% on placebo, with no ketoacidosis.8 Tirzepatide in type 1 rests on a single-centre observational cohort of 26 with no control arm
BPC-157 and TB-500, often combined in the Wolverine blend, are the recovery peptides most associated with tissue repair and post-training recovery
GLP1 receptor agonists improve glycemic control, promote weight loss, and reduce hepatic fat content effects that align with MASH treatment goals
Methionine is the essential amino acid precursor to several sulfur-containing antioxidants (including cysteine and glutathione), and sufficient dietary methionine is necessary for maintaining glutathione levels